It's been three months without a biotech IPO

D. Boral Capital Acted as Sole Bookrunner to Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) in connection with its $13.5 Million Initial Public Offering

NEW YORK CITY, NY / ACCESS Newswire / May 16, 2025 / On May 12, 2025, Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) ("Apimeds" or the "Company"), a clinical stage biopharmaceutical company that is in the process of developing Apitox, an intradermally…

It's been three months without a biotech IPO

The last time a biotech went public on a US stock exchange, people were buying flowers for Valentine's Day. Those petals withered long ago. It's been 13 weeks since Aardvark Therapeutics' $94 million initial public ...